Tarsus Pharmaceuticals, Inc. TARS Lessee Operating Lease Liability Undiscounted Excess Amount
Lessee Operating Lease Liability Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s lessee operating lease liability undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s lessee operating lease liability undiscounted excess amount?
- Tarsus Pharmaceuticals, Inc. (TARS) reported lessee operating lease liability undiscounted excess amount of $11.49M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s lessee operating lease liability undiscounted excess amount changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s lessee operating lease liability undiscounted excess amount increased by 81942.9% year-over-year, from $14K to $11.49M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s lessee operating lease liability undiscounted excess amount?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s lessee operating lease liability undiscounted excess amount has grown at a 150.2% compound annual growth rate (CAGR), from $122K to $11.96M.